In addition to the traditional clinicopathological risk factors, specific molecular profiles (e.g., BRAF, TERT, and RET) may be used to predict the risk of extrathyroidal extension and lymph node metastases (Xing et al., 2005; Lee et al., 2007; Kim et al., 2012). The gene discussed is RET; the disease is metastatic malignant neoplasm in the lymph nodes.